What is the GPS mdx test?

No additional office visits, no additional procedures. GPS mdx is a genomic test performed on tissue from your biopsy that is already in storage. The test looks at tumor DNA to see how the cancer is behaving.

Is the GPS mdx test right for you?

You may be a candidate if you have:

- ✓ Cancer contained to the prostate
- ✓ A prostate biopsy within 3 years
- ✓ Not yet started definitive treatment

Will your insurance cover GPS mdx?

Mdxhealth will work directly with your insurance provider to coordinate coverage. The vast majority of patients are responsible for \$250 or less. All patients are eligible for our financial assistance program.

For questions about insurance, contact our Patient Advocate Team.



866-259-7001



patientfirst@mdxhealth.com

mdxhealth



Xpert One Support is founded on personal attention, responsiveness, and commitment to customer satisfaction

Our Patient First Promise ensures mdxhealth tests are accessible and affordable for all patients. If you're facing financial challenges, contact an Xpert One Support patient advocate to find the right assistance options for you.



866-259-5644

Monday - Friday, 5:00AM - 5:00PM PT



info@mdxhealth.com

References

- ¹ Knezevic et al. BMC Genomics. 2013
- ² Klein et al. Eur Urol. 2014
- ³ Gearman et al. j Urol. 2018
- ⁴ Ellis et al. Ther Adv Urol. 2022
- ⁵ NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer. Version 1.2023.

Mdxhealth is regulated under the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP) as an accredited laboratory to perform high complexity clinical testing. This test was developed, and its performance characteristics determined by Mdxhealth. It has not been cleared or approved by the US Food and Drug Administration. The FDA has determined such clearance or approval is not necessary.

CLIA# 05D2033858; CAP# 8015399

IR-BROC-0172-R03





Navigating your prostate cancer journey

The Genomic Prostate Score (GPS mdx) test provides personalized results to help identify your risk of aggressive cancer and optimize your treatment selection.



Faster Answers. Better Care. GPS mdx NOW averages 5-day turnaround time

Why did my doctor order the GPS mdx test?

You recently underwent a prostate biopsy, and results indicated the presence of cancer cells within your prostate. Your doctor ordered the GPS mdx test to gather more information and examine your tumor's DNA to help identify the right treatment for you.^{1,2}

Due to the complexity of prostate cancer, 1 in 4 patients can have more aggressive disease at surgery when compared to their prostate biopsies.^{3,4} Which are you?



Studies have shown that 20% to 30% of patients have more aggressive cancer at prostate surgery than their prostate biopsies.^{3,4} GPS mdx can help us identify which patients are at a lower risk or a greater risk of more aggressive cancer, to help make treatment decisions.

Understanding your results

With the GPS mdx test results, we can use DNA to help predict how aggressive THIS tumor is. Higher results mean more aggressive disease. It also provides risk assessments for other long-term outcomes before starting treatment. The more information you have, the more informed your shared decision making can be.

Why does genomics matter?

Consider Bob and Joe. Based on PSA, imaging, and biopsy, both men have low aggressive disease and would be candidates for conservative treatment, such as active surveillance. Upon GPS mdx test results, their genomic results tell a different story. Bob has an aggressive tumor biology and may not be a good candidate for active surveillance.

	Bob	Joe
Age	68	68
PSA	6	7
MRI Results	PIRADS 3	PIRADS 3
Gleason Score	GG1: 3+3	GG1: 3+3
Genomic Prostate Score	42	12
Treatment Plan	More aggressive	Less aggressive
Treatment Plan		

What are my treatment options?

There are different treatment options for prostate cancer. As you discuss your options with your doctor, it is important to consider treatment side effects, your lifestyle, and the impact on your quality of life.

Active Surveillance	Surgery	Radiation Therapy	ADT
Least Aggressive			Most Aggressive

What will my test report tell me?

The Genomic Prostate Score helps you understand how aggressive the cancer is, and provides personalized risk assessments compared to prostate cancer patients with similar factors.

- How likely you are to die from prostate cancer within 10 years.
- How likely your cancer is to spread outside of the prostate within 10 years.
- How likely are you to find more aggressive cancer if you undergo surgery.